CYTK Earnings Date: Nov 4, 2026 (Estimated) — Cytokinetics, Incorporated
NASDAQ · Healthcare · Biotechnology
Updated
When is CYTK's next earnings date?
Cytokinetics, Incorporated (CYTK) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.44 on revenue of $41.2M.
How did CYTK do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Cytokinetics, Incorporated posted EPS of -$1.50 versus the -$1.63 estimate, a beat of 7.4%. Revenue was $28.6M against a $17.6M estimate. The stock's 1-day post-earnings move was -5.7%.
How much does CYTK stock move after earnings?
CYTK beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.8% (up or down) in the day after earnings.
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -1.63 | -1.50 | +7.41% | $28.6M | ✅ Beat | -5.67% | -9.73% | -10.63% |
| 2026-05-05 | Q1 2026 | -1.65 | -1.67 | -1.21% | $19.4M | ❌ Miss | -2.92% | -2.96% | -6.23% |
| 2026-02-24 | Q4 2025 | -1.41 | -1.50 | -6.38% | $17.8M | ❌ Miss | -10.29% | -13.38% | -11.00% |
| 2025-11-05 | Q3 2025 | -1.58 | -1.54 | +2.53% | $1.9M | ✅ Beat | +1.88% | +11.40% | +10.95% |
| 2025-08-07 | Q2 2025 | -1.35 | -1.12 | +17.04% | $66.8M | ✅ Beat | -3.23% | +9.84% | +47.77% |
| 2025-05-06 | Q1 2025 | -1.36 | -1.36 | +0.00% | $1.6M | ➖ Inline | -2.74% | -9.89% | -5.56% |
| 2025-02-27 | Q4 2024 | -1.17 | -1.26 | -7.69% | $16.9M | ❌ Miss | -3.06% | -8.81% | -8.98% |
| 2024-11-06 | Q3 2024 | -1.26 | -1.36 | -7.94% | $463,000 | ❌ Miss | +0.61% | +0.83% | -8.18% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $28.6M total
| Segment | Share | Revenue | YoY | Q2 FY24 | Q3 FY24 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Net Product Revenue | 88.5% | $25.3M | — | — | — | — | — |
| Collaboration Revenues | 11.5% | $3.3M | +36.2% | — | — | $2.4M | $1.9M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.